Actively Recruiting
FaCT Trial (Facilitated Cascade Testing Trial)
Led by Weill Medical College of Cornell University · Updated on 2025-10-01
820
Participants Needed
3
Research Sites
279 weeks
Total Duration
On this page
Sponsors
W
Weill Medical College of Cornell University
Lead Sponsor
B
Basser Research Center for BRCA
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to assess an intervention that incorporates engagement strategies with a medical team navigator, an educational video and accessible genetic testing services to maximize the genetic testing and education of at-risk relatives. In this study, first degree relatives who agree to participate will either receive this intervention or standard of care. The investigators do not know if the facilitated interventional method will be more effective than the standard of care method. This research is being done because identification of patients with inherited gynecologic/breast cancer syndromes is critical to enable delivery of tailored cancer treatment and cancer prevention to both the patients and their at-risk relatives. Cascade genetic testing, defined as extending genetic testing to the family members of affected patients, results in a more precise risk assessment and initiation of appropriate cancer screening and prevention strategies. Therefore, this trial will compare the efficacy of a multicomponent facilitated intervention for first degree relatives vs. standard of care in terms of the overall proportion of first degree relatives who complete genetic testing by 6 months (primary outcome).
CONDITIONS
Official Title
FaCT Trial (Facilitated Cascade Testing Trial)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older as documented in the medical record
- Speaks and reads English or Spanish as reported by the patient
- Currently receiving diagnostic, treatment, or follow-up care at New York Presbyterian/Weill Cornell Medical Center, MD Anderson Cancer Center, Duke University, or Columbia University
- Newly diagnosed with BRCA mutation or diagnosed with a confirmed deleterious BRCA1 or BRCA2 variant within the last 12 months
- BRCA1/2 mutation included on testing panel provided by the clinical genetic testing laboratory
- Has at least one at-risk first degree relative
You will not qualify if you...
- Unwilling or unable to provide informed consent
- Does not have email access
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Weill Cornell Medicine
New York, New York, United States, 10065
Actively Recruiting
2
Duke University
Durham, North Carolina, United States, 27710
Actively Recruiting
3
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
M
Melissa K Frey, MD, MS
CONTACT
I
Isabelle R Chandler
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here